De Novo device
MammaPrint
Agendia, Inc. · Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer (NYI, Class II) · First FDA decision Feb 6, 2007, newest Nov 5, 2020Breast cancer
Last checked: Nov 21, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
De Novo pathway
Device trials
1
Naming "MammaPrint"
MAUDE reports
0
Brand "MammaPrint", since 2015
PubMed studies
420
Mentioning "MammaPrint"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing MammaPrint
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- MammaPrint510(k)
K201902 · Decided Nov 5, 2020 · 120 days after receipt
Device type: Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer (NYI) · Laboratory Medicine & Pathology
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Prognostic and Predictive Molecular Classifiers for Bladder CancerLocal determinationIn effectL38586CGS Administrators, LLCUpdated May 11, 2026
- MolDX: Prognostic and Predictive Molecular Classifiers for Bladder CancerLocal determinationIn effectL38684WPS Insurance CorporationUpdated Apr 10, 2026
- MolDX: Prognostic and Predictive Molecular Classifiers for Bladder CancerLocal determinationIn effectL38647Noridian Healthcare Solutions, LLCUpdated Apr 7, 2026
- MolDX: Prognostic and Predictive Molecular Classifiers for Bladder CancerLocal determinationIn effectL38576Palmetto GBAUpdated Apr 7, 2026
- MolDX: EndoPredict Breast Cancer Gene Expression TestLocal determinationIn effectL37356CGS Administrators, LLCUpdated Apr 6, 2026
- MolDX: Breast Cancer Index® (BCI) Gene Expression TestLocal determinationIn effectL37913WPS Insurance CorporationUpdated Feb 20, 2026
- MolDX: Breast Cancer Index® (BCI) Gene Expression TestLocal determinationIn effectL37822Noridian Healthcare Solutions, LLCUpdated Jan 12, 2026
- MolDX: EndoPredict® Breast Cancer Gene Expression TestLocal determinationIn effectL37295Noridian Healthcare Solutions, LLCUpdated Jan 12, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "MammaPrint", any status and sponsor, newest update first.
AgendiaNot on our public-company list
NCT01617954 · 820 participants · Start May 2012 · Primary completion Dec 2015
Device: MammaPrint · For: Hormone Receptor Positive Malignant Neoplasm of Breast
Sites: Phoenix, Arizona; Burbank, California; Palm Springs, California · 53 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "MammaPrint", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NYI
1 reports: 0 malfunction, 1 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1321-2010 · Started Mar 3, 2010 · Posted by FDA Apr 12, 2010
Reason given: Over a period of about 6 months in about 15% of results provided Agendia has been "over reporting" the chance of metastasis risk being 29% risk of recurrence instead of 10% risk. This over reporting of risk did not cause direct injury to patients. However, if used by physicians as the sole basis for decision-making,...
Cause as FDA categorized it: Other · Device type: Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer (NYI)
Published research
The most relevant PubMed records for "MammaPrint"[tiab]. The summary above synthesizes these.
- Mammaprintࡊ: a comprehensive review.
Brandão M, Pondé N, Piccart-Gebhart M · Future Oncol · 2019
- MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data.
Brufsky AM, Hoskins KF, Conter HJ, et al. · JNCI Cancer Spectr · 2025Observational Study
- MammaPrint Reduces Breast Cancer Overtreatment.
Cancer Discov · 2016News
- MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue.
Sapino A, Roepman P, Linn SC, et al. · J Mol Diagn · 2014Research Support, Non-U.S. Gov't
- 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
Cardoso F, van't Veer LJ, Bogaerts J, et al. · N Engl J Med · 2016Clinical Trial, Phase III, Multicenter Study
- MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early-stage breast cancer patients.
Haan JC, Bhaskaran R, Ellappalayam A, et al. · Genes Chromosomes Cancer · 2022
- Recent advances in breast cancer treatment.
Levva S · Hell J Nucl Med · 2023
- MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology.
Mittempergher L, Delahaye LJMJ, Witteveen AT, et al. · J Mol Diagn · 2019Research Support, Non-U.S. Gov't
- Prediction of the MammaPrint Risk Group Using MRI Features in Women With Estrogen Receptor-Positive, HER2-Negative, and 1 to 3 Node-Positive Invasive Breast Cancer.
Kim HJ, Choi WJ, Cha JH, et al. · Clin Breast Cancer · 2024
- Cost-Effectiveness Analysis of MammaPrint® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer.
Luyendijk M, Jager A, Buijs SM, et al. · Pharmacoeconomics · 2023
- Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.
Andre F, Ismaila N, Allison KH, et al. · J Clin Oncol · 2022Research Support, N.I.H., Extramural, Practice Guideline
- Breast Cancer: A Heterogeneous Pathology. Prognostic and Predictive Factors - A Narrative Review.
Popa MT, Nodi£i A, Peleaşg TM, et al. · Chirurgia (Bucur) · 2025Review
Other devices of this type
Also filed under product code NYI.
- Prosigna Breast Cancer Prognostic Gene Signature AssayNanostring Technologies, Inc. · 510(k) 2014
- Modification to MammaprintAgendia · 510(k) 2009
- MammaPrint FFPE NGS KitAgendia, Inc. · 510(k) 2022
- Mammaprint FfpeAgendia · 510(k) 2015
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.